Cancer is often rendered an uncurable disease, which poses a great threat to human health worldwide. Among all kinds of cancers, gynecological cancers (including breast, ovarian, cervical, and endometrial cancer) and gastrointestinal cancers (including gastric, colorectal, liver, and pancreatic cancer) are the most common cancer types worldwide (Ciou et al., 2022; Murphy et al., 2018). Although chemotherapy, radiotherapy, and surgical excision are commonly used to treat these gynecological and gastrointestinal cancers, cancer cells frequently develop resistance to conventional cancer therapy due to a variety of mechanisms (Davern et al., 2020; Marchetti et al., 2021). Accordingly, new therapeutic strategies such as the identification of novel potential molecular targets or biomarkers, as well as the development of new molecular diagnostic approaches and targeted therapy (e.g., proteins, transcription factors, non-coding RNA, targeted small-molecule drugs, etc.) are greatly needed to overcome inherent and acquired resistance, which would provide a promising therapeutic approach for the treatment of various gynecological and gastrointestinal cancers.
Breast cancer is the most common global malignancy and one of the most serious gynecological cancers affecting women, which also represents currently a top biomedical research priority (Akram et al., 2017). And its incidence and mortality rates are expected to increase continuously the next years (Barzaman et al., 2020). Accumulating evidence suggests that circular RNAs (circRNAs) are highly correlated with tumor progression and pathogenesis in breast cancer (Sang et al., 2019). Whereas, their regulatory roles and corresponding mechanisms in breast cancer are still unknown to some extent. Therefore, Lin et al. explored the circRNA-mediated competive endogenous RNA (ceRNA) network to uncover the possible roles and clinical implications of circRNAs in breast cancer. Through functional experiments, they found that the depletion of two circRNAs, circ_0008812 and circ_0001583, could significantly inhibit the proliferation of MCF-7 cells, providing a new perspective into the molecular mechanisms of breast cancer pathogenesis.
Pancreatic adenocarcinoma (PAAD) is the most common primary malignancy of the pancreas and is a highly aggressive tumor that is almost uniformly lethal in humans (Ge et al., 2022). According to previous research, the APOBEC family is associated with development of a variety of cancers (Mertz et al., 2022). Duan et al. discovered that APOBEC1/3A/3G/3H showed significantly elevated expression in PAAD than para-cancerous or normal tissues, indicating they have the potential to serve as novel biomarkers or therapeutic targets. Furthermore, recent evidence uncovered by Duan et al. suggests that SUMO family member is closely related to the occurrence and development of PAAD, which can also be used as a new biomarker and therapeutic target for patients with PAAD.
Colorectal cancer (CRC) is the third most common cancer and the second leading cause of cancer-related deaths in the world (Dekker et al., 2019). In addition, the incidence of CRC is increasing continuously in some areas of the world (Issa et al., 2017). Yunos et al. identified specific druggable somatic mutations by using the whole-genome sequencing approach on Malaysian patients, which could be of great benefit especially to Malaysian CRC patients. To note, at least one druggable somatic alteration was identified in 88% of the Malaysian CRC patients. Among them were two frameshift mutations in RNF43 (G156fs and P192fs) predicted to have responsive effects against the Wnt pathway inhibitor. Collectively, this research highlighted the potential of an alternative treatment targeting Wnt/Beta Catenin signaling pathway using whole genome sequencing, providing a new idea for the treatment of colorectal cancer. In addition, high expression of long non-coding RNA small nucleolar RNA host genes (lncRNA SNHGs) was revealed to be positively associated with poor CRC prognosis by Luo et al. Thus, lncRNA SNHG could serve as a potential prognostic indicator and therapeutic target for CRC.
In summary, the Research Topic “Gynecological and gastrointestinal cancers: Recent advances in molecular diagnosis and targeted therapy” collects studies focused on finding novel biomarkers and therapeutic targets in various gynecological and gastrointestinal cancers. The articles in this Research Topic highlight important, interrelated Research Topic and will hopefully serve as a catalyst for further studies that pave the way for developing novel targeting therapeutic strategies for cancers and overcoming therapeutic resistance. Ultimately, we trust that these efforts may eventually help improve survival outcomes and prognoses for gynecological and gastrointestinal cancer patients in the future.
Statements
Author contributions
LZ and JZ contributed to the writing and reviewing of this editorial. All authors contributed to the article and approved the submitted version.
Funding
This work was mainly supported by grants from Fundamental Research Funds for the Central Universities (Grant No. 2682022ZTPY032) and Shenzhen Science and Technology Research and Development Funds (Grant No. JCYJ20210324094612035).
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1
AkramM.IqbalM.DaniyalM.KhanA. U. (2017). Awareness and current knowledge of breast cancer. Biol. Res.50 (1), 33. 10.1186/s40659-017-0140-9
2
BarzamanK.KaramiJ.ZareiZ.HosseinzadehA.KazemiM. H.Moradi-KalbolandiS.et al (2020). Breast cancer: Biology, biomarkers, and treatments. Int. Immunopharmacol.84, 106535. 10.1016/j.intimp.2020.106535
3
CiouH. H.LeeT. H.WangH. C.DingY. R.TsengC. J.WangP. H.et al (2022). Repurposing gestrinone for tumor suppressor through P21 reduction regulated by JNK in gynecological cancer. Transl. Res.243, 21–32. 10.1016/j.trsl.2021.12.002
4
DavernM.LysaghtJ. (2020). Cooperation between chemotherapy and immunotherapy in gastroesophageal cancers. Cancer Lett.495, 89–99. 10.1016/j.canlet.2020.09.014
5
DekkerE.TanisP. J.VleugelsJ. L. A.KasiP. M.WallaceM. B. (2019). Colorectal cancer. Lancet394 (10207), 1467–1480. 10.1016/S0140-6736(19)32319-0
6
GeW.GogaA.HeY.SilvaP. N.HirtC. K.HerrmannsK.et al (2022). miR-802 suppresses acinar-to-ductal reprogramming during early pancreatitis and pancreatic carcinogenesis. Gastroenterology162 (1), 269–284. 10.1053/j.gastro.2021.09.029
7
IssaI. A.NoureddineM. (2017). Colorectal cancer screening: An updated review of the available options. World J. Gastroenterol.23 (28), 5086–5096. 10.3748/wjg.v23.i28.5086
8
MarchettiC.De FeliceF.RomitoA.IacobelliV.SassuC. M.CorradoG.et al (2021). Chemotherapy resistance in epithelial ovarian cancer: Mechanisms and emerging treatments. Semin. Cancer Biol.77, 144–166. 10.1016/j.semcancer.2021.08.011
9
MertzT. M.CollinsC. D.DennisM.CoxonM.RobertsS. A. (2022). APOBEC-induced mutagenesis in cancer. Annu. Rev. Genet.56, 229–252. 10.1146/annurev-genet-072920-035840
10
MurphyN.JenabM.GunterM. J. (2018). Adiposity and gastrointestinal cancers: Epidemiology, mechanisms and future directions. Nat. Rev. Gastroenterol. Hepatol.15 (11), 659–670. 10.1038/s41575-018-0038-1
11
SangY.ChenB.SongX.LiY.LiangY.HanD.et al (2019). circRNA_0025202 regulates tamoxifen sensitivity and tumor progression via regulating the miR-182-5p/FOXO3a Axis in breast cancer. Mol. Ther.27 (9), 1638–1652. 10.1016/j.ymthe.2019.05.011
Summary
Keywords
breast cancer, pancreatic adenocarcinoma, colorectal cancer, prognosis, molecular mechanisms, targeted therapy
Citation
Zhang L, Wang G, Zhu L, Wei W and Zhang J (2023) Editorial: Gynecological and gastrointestinal cancers: Recent advances in molecular diagnosis and targeted therapy. Front. Mol. Biosci. 10:1167337. doi: 10.3389/fmolb.2023.1167337
Received
16 February 2023
Accepted
24 February 2023
Published
03 March 2023
Volume
10 - 2023
Edited by
William C. Cho, QEH, Hong Kong SAR, China
Reviewed by
Teresa Rubio-Tomás, University of Crete, Greece
Updates
Copyright
© 2023 Zhang, Wang, Zhu, Wei and Zhang.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Lan Zhang, zhanglanx_9@126.com; Jin Zhang, zhangjin1989@szu.edu.cn
This article was submitted to Molecular Diagnostics and Therapeutics, a section of the journal Frontiers in Molecular Biosciences
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.